Loading stock data…
NextCure, Inc. (NXTC)
$4.24+0.06 (+1.44%)
Market ClosedLast close Jul 24
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
NextCure, Inc. in the Healthcare sector is trading at $4.24 with a market capitalization of $22M. Wall Street consensus targets $20.00 (3 analysts), implying a +371.7% move over the next 12 months. The stock is currently near its 52-week low of $1.55, remaining 55.6% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 25/100 signals elevated caution as multiple indicators diverge.
Ecosystem Influences
Sell-side targets imply +371.7% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$10.11M↓ | -$9.76M↓ | -$8.95M↑ | -$27.29M↓ | -$11.62M |
| Net Income | -$9.80M↓ | -$9.44M↓ | -$8.62M↑ | -$26.81M↓ | -$10.98M |
Peer Comparison
JNJUNHPFE
Fundamentals
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that i...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$22.39M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-204.61%
Volume
Today's trading volume
280,712
Recent News
Sector Update: Healthcare Stocks Fall Late Afternoon
Healthcare stocks fell late Tuesday afternoon with the NYSE Healthcare Index declining 1.7% and the
Fresh off buyout, Akero execs reunite to advance long-acting psoriasis pill
Set to go public via a reverse merger, Avere has licensed from a prolific Chinese drugmaker rights to a potential threat to medicines like Skyrizi and Icotyde.
Does NextCure (NXTC) Have the Potential to Rally 107.88% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 107.9% in NextCure (NXTC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Companies Like NextCure (NASDAQ:NXTC) Could Be Quite Risky
We can readily understand why investors are attracted to unprofitable companies. For example, although...